{"title":"PEDF肽的抗癌潜力。","authors":"Enas Bani-Ahmad, Joshua Dass, Crispin R Dass","doi":"10.1093/jpp/rgaf043","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>Pigment epithelium-derived factor (PEDF) has demonstrated a wide range of activities, the most notable of which is its role in cancer.</p><p><strong>Methods: </strong>Articles were sourced from Scopus with the following keywords-PEDF, peptide(s), cancer, tumour, and tumour. There was no limit set on date of publication, and the language of publication was set to English.</p><p><strong>Key findings: </strong>Researchers have found two functional epitopes in the PEDF sequence: a 34-mer peptide that mainly inhibits angiogenesis and a 44-mer peptide that mainly promotes differentiation and neurotrophic functions in certain cell lines. Furthermore, studies have demonstrated that shorter peptides in the 34-mer significantly contribute to its angiogenic activity. PEDF peptide functions as an anticancer agent through various mechanisms. The most salient feature is the blockade of angiogenesis by reducing VEGF levels. Angiogenesis is critical in tumour expansion, and it is known as the process whereby new blood vessels are formed from capillaries.</p><p><strong>Conclusions: </strong>Researchers have studied several PEDF peptides in various types of cancer, including ovarian, breast, lung, osteosarcoma, and myeloma. This underscores the potential significance of the various PEDF peptides, given their known ability to influence angiogenesis and other biological processes.</p>","PeriodicalId":16960,"journal":{"name":"Journal of Pharmacy and Pharmacology","volume":" ","pages":""},"PeriodicalIF":2.8000,"publicationDate":"2025-06-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Anticancer potential of PEDF peptides.\",\"authors\":\"Enas Bani-Ahmad, Joshua Dass, Crispin R Dass\",\"doi\":\"10.1093/jpp/rgaf043\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objectives: </strong>Pigment epithelium-derived factor (PEDF) has demonstrated a wide range of activities, the most notable of which is its role in cancer.</p><p><strong>Methods: </strong>Articles were sourced from Scopus with the following keywords-PEDF, peptide(s), cancer, tumour, and tumour. There was no limit set on date of publication, and the language of publication was set to English.</p><p><strong>Key findings: </strong>Researchers have found two functional epitopes in the PEDF sequence: a 34-mer peptide that mainly inhibits angiogenesis and a 44-mer peptide that mainly promotes differentiation and neurotrophic functions in certain cell lines. Furthermore, studies have demonstrated that shorter peptides in the 34-mer significantly contribute to its angiogenic activity. PEDF peptide functions as an anticancer agent through various mechanisms. The most salient feature is the blockade of angiogenesis by reducing VEGF levels. Angiogenesis is critical in tumour expansion, and it is known as the process whereby new blood vessels are formed from capillaries.</p><p><strong>Conclusions: </strong>Researchers have studied several PEDF peptides in various types of cancer, including ovarian, breast, lung, osteosarcoma, and myeloma. This underscores the potential significance of the various PEDF peptides, given their known ability to influence angiogenesis and other biological processes.</p>\",\"PeriodicalId\":16960,\"journal\":{\"name\":\"Journal of Pharmacy and Pharmacology\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":2.8000,\"publicationDate\":\"2025-06-13\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Pharmacy and Pharmacology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1093/jpp/rgaf043\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Pharmacy and Pharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/jpp/rgaf043","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
Objectives: Pigment epithelium-derived factor (PEDF) has demonstrated a wide range of activities, the most notable of which is its role in cancer.
Methods: Articles were sourced from Scopus with the following keywords-PEDF, peptide(s), cancer, tumour, and tumour. There was no limit set on date of publication, and the language of publication was set to English.
Key findings: Researchers have found two functional epitopes in the PEDF sequence: a 34-mer peptide that mainly inhibits angiogenesis and a 44-mer peptide that mainly promotes differentiation and neurotrophic functions in certain cell lines. Furthermore, studies have demonstrated that shorter peptides in the 34-mer significantly contribute to its angiogenic activity. PEDF peptide functions as an anticancer agent through various mechanisms. The most salient feature is the blockade of angiogenesis by reducing VEGF levels. Angiogenesis is critical in tumour expansion, and it is known as the process whereby new blood vessels are formed from capillaries.
Conclusions: Researchers have studied several PEDF peptides in various types of cancer, including ovarian, breast, lung, osteosarcoma, and myeloma. This underscores the potential significance of the various PEDF peptides, given their known ability to influence angiogenesis and other biological processes.
期刊介绍:
JPP keeps pace with new research on how drug action may be optimized by new technologies, and attention is given to understanding and improving drug interactions in the body. At the same time, the journal maintains its established and well-respected core strengths in areas such as pharmaceutics and drug delivery, experimental and clinical pharmacology, biopharmaceutics and drug disposition, and drugs from natural sources. JPP publishes at least one special issue on a topical theme each year.